Actinium presents preclinical SNMMI 2026 data showing ATNM-400 beats KRAS inhibitors in NSCLC models

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00
  • Actinium Pharmaceuticals presented new preclinical ATNM-400 data at SNMMI 2026 on June 2, 2026, targeting a broader NSCLC treatment approach.
  • Studies indicated ATNM-400 produced stronger tumor control than leading KRAS inhibitors when used alone in KRAS-mutant models.
  • Combination regimens with KRAS inhibitors or the EGFR drug osimertinib showed enhanced responses, including complete tumor regression in an EGFR-mutant model.
  • Results support a mutation-agnostic development strategy in NSCLC, positioning ATNM-400 as a potential backbone therapy across large patient segments.
  • Commercial framing highlighted sizable adjacent markets, including KRAS inhibitors projected above USD 5 billion peak sales and EGFR-mutant therapies above USD 15 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606030800PR_NEWS_USPR_____NY74587) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.